Press Release: HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Humacyte, Inc. on Behalf of Humacyte Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) on behalf of Humacyte stockholders. Our investigation concerns whether Humacyte has violated the federal securities laws and/or engaged in other unlawful business…
Press Release: HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Humacyte, Inc. on Behalf of Humacyte Stockholders and Encourages Investors to Contact the Firm - Newscast
Wed, 05 Mar 2025 10:00:00 GMT Humacyte, Inc. (HUMA) ended the recent trading session at $3.15, demonstrating a -1.56% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain ...
Thu, 27 Feb 2025 13:05:00 GMT For more information, visit www.Humacyte.com. This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases ...
Thu, 27 Feb 2025 07:01:00 GMT In the latest market close, Humacyte, Inc. (HUMA) reached $3.37, with a -1.75% movement compared to the previous day. This move lagged the S&P 500's daily loss of 1.59%. Meanwhile, the Dow ...
Wed, 26 Feb 2025 05:00:00 GMT DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq ... sale by the FDA or any other regulatory agency. This press release contains forward-looking statements that are based ...
